Predictors of Development of Hepatocellular Carcinoma in Non-Cirrhotic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis - A Retrospective Analysis of the National Inpatient Sample

This study provides compelling evidence that HCC can develop in non-cirrhotic MASLD/MASH patients. These findings highlight an urgent need to shift from a cirrhosis-centric approach to a more comprehensive, risk-based HCC screening model - especially given that MASLD/MASH is now the most common and fastest-growing etiology of HCC around the globe. This study can potentially help develop those screening guidelines to prevent the development or early detection of HCC in non-cirrhotic MASLD/MASH patients.